Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201) [Phase 2]

View source ↗

Summary

Phase 2 results update evaluating the efficacy and safety of pemigatinib (INCB054828) in patients with urothelial carcinoma (FIGHT-201). Results were posted on …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma

Drugs mentioned

• Pemazyre (pemigatinib)

Snippet

Sponsor: Incyte Corporation | Conditions: UC (Urothelial Cancer) | Phase 2 | Status: COMPLETED | Results posted: 2023-03-24